NCT04446416View on ClinicalTrials.gov

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

August 4, 2023

Conditions
Glioblastoma MultiformeGlioblastomaGliomaBrain TumorNeoplasmsNeoplasms, Nerve Tissue
Interventions
DEVICE

NaviFUS System

Open the BBB using focused ultrasound and contrast agent SonoVue®

DRUG

Bevacizumab

An anti-angiogenic agent to block tumor growth

Trial Locations (1)

33305

Linkou Chang Gung Memorial Hospital, Taoyuan

Sponsors
All Listed Sponsors
collaborator

Chang Gung Memorial Hospital

OTHER

lead

NaviFUS Corporation

INDUSTRY